Myovant Sciences updates positive data from Phase 3 prostate cancer trial

Myovant Sciences’ (NASDAQ:MYOV) reported additional positive results from its Phase 3 HERO study of once-daily, oral relugolix in men with advanced prostate cancer.

In the primary endpoint responder analysis, 97% of men receiving relugolix achieved sustained testosterone suppression to castrate levels through 48 weeks, compared with 89% of men treated with leuprolide acetate.

In the relugolix group, testosterone suppression to less than 50 nanograms per deciliter was achieved in 56% of men by day 4 and 99% by day 15, compared with 0% by day 4 and 12% by day 15 for men in the leuprolide acetate group.

In addition, men in the relugolix group had a 54% lower risk of major adverse cardiovascular events compared with the leuprolide acetate group.

“A faster effect in lowering testosterone for prostate cancer patients can be clinically significant – likewise, a more rapid testosterone recovery after stopping treatment, could potentially improve a patient’s quality of life,” Dr. Neal Shore, medical director of the Carolina Urologic Research Center, said in a statement.

“An oral therapeutic option with strong efficacy that also reduces cardiovascular risk compared to that of conventional gonadotropin-releasing hormone agonist therapy would be a critical achievement for men with advanced prostate cancer,” he added.

Myovant submitted an NDA to the FDA for relugolix in April 2020.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.